Brookline downgraded Syros Pharmaceuticals (SYRS) to Hold from Buy. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on SYRS: Syros Pharmaceuticals trading resumes Syros Pharmaceuticals says SELECT-MDS-1 trial did not meet primary endpoint Syros Pharmaceuticals trading halted, news pending Syros Pharmaceuticals Reports Q3 2024 Financial Results Syros Pharmaceuticals reports Q3 EPS (16c), consensus (72c)